Enzymatica AB (FRA:EN9) Beta: -4.9893 (As of Jul. 06, 2026)


FRA:EN9 Enzymatica AB FRA:EN9
36 GF Score
Price €0.20
GF Value €0.17
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB Beta?

Enzymatica AB FRA:EN9 +3.17% 36 Beta is -4.9893 as of Jul. 06, 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 36/100 and a GF Value™ of €0.17 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), Enzymatica AB's Beta is -4.9893.


Enzymatica AB  (FRA:EN9) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Enzymatica AB Beta Related Terms


Enzymatica AB Beta Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Beta Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.96 -0.07 0.27

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -1.37 -2.85 0.27 -3.96

FRA:EN9 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Beta distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Beta falls into.


FRA:EN9
36GF Score
Enzymatica AB FRA:EN9
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -4.9893 mean?
Enzymatica AB (FRA:EN9) has a Beta of -4.9893 as of Jul. 06, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Enzymatica AB and its competitors.
Is Enzymatica AB's Beta too high?
Enzymatica AB's current Beta is -4.9893. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Beta compare to ZTS and UTHR?
Enzymatica AB's Beta of -4.9893 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Enzymatica AB and its competitors. Enzymatica AB's current Beta is -4.9893. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.20 — trading 14.7% above its estimated fair value. The current Beta is -4.9893. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Beta is -4.9893 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.20 is trading 14.7% above its estimated GF Value™ of €0.17. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

  • Beta: -4.9893
  • GF Value™: €0.17 vs. price of €0.20 (14.7% above fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score

Get the complete analysis for FRA:EN9

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.17
GF Value